BioCentury
ARTICLE | Clinical News

Valtaxin valrubicin chemotherapeutic anthracycline derivative regulatory update

July 24, 2000 7:00 AM UTC

Canada granted marketing approval for PLB's Valtaxin for intravesical therapy of refractory carcinoma in situ (CIS) of the bladder. PLB acquired Canadian rights to the compound, which is marketed in t...